Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-cash Items (2019 - 2025)

Vivos Therapeutics' Non-cash Items history spans 7 years, with the latest figure at $163000.0 for Q3 2025.

  • Quarterly results put Non-cash Items at $163000.0 for Q3 2025, up 34.71% from a year ago — trailing twelve months through Sep 2025 was $163000.0 (up 34.71% YoY), and the annual figure for FY2024 was $121000.0, up 35.96%.
  • Non-cash Items for Q3 2025 was $163000.0 at Vivos Therapeutics, down from $174000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $4.0 million in Q1 2021 to a low of $88000.0 in Q3 2023.
  • The 5-year median for Non-cash Items is $163000.0 (2025), against an average of $861664.2.
  • Peak annual rise in Non-cash Items hit 119.75% in 2023, while the deepest fall reached 95.96% in 2023.
  • Year by year, Non-cash Items stood at $1.7 million in 2021, then tumbled by 94.74% to $90000.0 in 2022, then dropped by 1.11% to $89000.0 in 2023, then skyrocketed by 35.96% to $121000.0 in 2024, then surged by 34.71% to $163000.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $163000.0, $174000.0, and $151000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.